*PLEASE READ!!*

**HELENA LABORATORIES**

**PROCEDURE DOWNLOAD END USER AGREEMENT**

In response to customer requests, Helena is pleased to provide the text for procedural package inserts in a digital format editable for your use. The text for the procedure you requested begins on page three of this document. Helena procedures contain the content outlined in the NCCLS (GP2-A#) format, except in the order sequence required by FDA regulations. As the NCCLS format is a guideline, you may retain these procedures as developed by the manufacturer (adding your title/authorization page) or manipulate the text file to produce your own document, matching the NCCLS section order exactly, if preferred.

We also provide the procedure in an Adobe Acrobat PDF format for download at www.helena.com as a “MASTER” file copy. Below are the specifications and requirements for using these digital files. Following the specifications is the procedure major heading sequence as given in the FDA style. Where there is a difference in order, or other notation in the outline, this will be indicated in braces { }.

WHAT YOU NEED TO KNOW:

1) These files represent the most current revision level to date. Your current product inventory could contain a previous revision level of this procedure.

2) The Microsoft Word document provides the text only from the master procedure, in a single-column format.

* It may not contain any illustrations, graphics or captions that may be part of the master procedure included in the kit.
* The master procedure may have contained special formatting characters, such as subscripts, superscripts, degree symbols, mean symbols and Greek characters such as alpha, beta, gamma, etc. These symbols may or may not display properly on your desktop.
* The master procedures may also contain columns of tabbed data. Tab settings may or may not be displayed properly on your desktop.

3) The Adobe Acrobat PDF file provides a snapshot of the master procedure in a printable 8.5 x 11” format. It is provided to serve as a reference for accuracy.

4) By downloading this procedure, your institution is assuming responsibility for modification and usage.

**HELENA LABORATORIES**

**PROCEDURE DOWNLOAD END USER AGREEMENT**

HELENA LABORATORIES LABELING – Style/Format Outline

1. PRODUCT {Test} NAME
2. INTENDED USE and TEST TYPE (qualitative or qualitative)
3. SUMMARY AND EXPLANATION
4. PRINCIPLES OF THE PROCEDURE

{*NCCLS lists SAMPLE COLLECTION/HANDLING next}*

1. REAGENTS (name/concentration; warnings/precautions; preparation; storage; environment; Purification/treatment; indications of instability)
2. INSTRUMENTS required – Refer to Operator Manual (... for equipment for; use or function; Installation; Principles of operation; performance; Operating Instructions; Calibration\* {\*is next in order for NCCLS – also listed in “PROCEDURE”}’ precautions/limitations/hazards; Service and maintenance information
3. SAMPLE COLLECTION/HANDLING
4. PROCEDURE

{*NCCLS lists QUALITY CONTROL (QC) next}*

9) RESULTS (calculations, as applicable; etc.)

10) LIMITATIONS/NOTES/INTERFERENCES

11) EXPECTED VALUES

12) PERFORMANCE CHARACTERISTCS

13) BIBLIOGRAPHY (of pertinent references)

14) NAME AND PLACE OF BUSINESS OF MANUFACTURER

15) DATE OF ISSUANCE OF LABELING (instructions)

For Sales, Technical and Order Information, and Service Assistance,   
call Helena Laboratories toll free at 1-800-231-5663.

Form 364

Helena Laboratories

1/2006 (Rev 3)

## Cat. No. 3430

**SPIFE® Touch SPE Hi Res-20 Procedure**

The SPIFE Touch High Resolution Protein method is intended for the qualitative separation of protein fractions in serum, cerebrospinal fluid (CSF) or urine using agarose gel electrophoresis on the SPIFE Touch system.

**SUMMARY**

High resolution electrophoresis achieves better resolution of the proteins beyond the classical five band patterns, thereby increasing the diagnostic usefulness of protein patterns.1-3 Approximately fifteen serum proteins have been studied extensively because they may be measured easily.4-7 In this context, high resolution electrophoresis refers to systems which separate 95% of the total protein mass into 10 to 15 discrete fractions.

**PRINCIPLE**

Proteins are large molecules composed of covalently linked amino acids. Proteins can be either polar or nonpolar at a given pH depending on electron distributions resulting from covalent or ionic bonding of structural subgroups. In the Helena procedure, proteins are separated according to their respective electrical charges on agarose gel, using both the electrophoretic and electroendosmotic forces present in the system. The separations are stained with a protein sensitive stain.

**REAGENT**

**1. SPIFE SPE Hi Res Gel   
Ingredients:** Each gel contains agarose in Tris barbital buffer, sorbitol and a preservative.   
**WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. DO NOT INGEST.** The gel contains barbital which, in sufficient quantity, can be toxic.   
**Preparation for Use:** The gels are ready for use as packaged.   
**Storage and Stability:** The gels should be stored at room temperature (15 to 30°C) and are stable until the expiration date indicated on the package. The gels must be stored in the protective packaging in which they are shipped. **DO NOT REFRIGERATE OR FREEZE THE GELS**.  **Signs of Deterioration:** Any of the following conditions may indicate deterioration of the gel: (1) crystalline appearance indicating the agarose has been frozen, (2) cracking and peeling indicating drying of the agarose, (3) bacterial growth indicating contamination, (4) thinning of the gel blocks.

**2. Acid Violet Stain**

**Ingredients:** The stain contains Acid Violet.   
**WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. DO NOT INGEST.   
Preparation for Use:** Dissolve the dry stain in 1 L 10% acetic acid. Filter before use, if necessary, then fill the stain vat.   
**Storage and Stability:** The dry stain should be stored at 15 to 30°C and is stable until the expiration date indicated on the package. The stain solution is stable for six months when stored at 15 to 30°C in a closed container. **Signs of Deterioration:** The diluted stain should be an homogeneous mixture free of precipitate. This stain must be replaced after processing 10 gels to avoid contamination.

**3. Citric Acid Destain   
Ingredients:** After dissolution, the destain contains 0.3% (w/v) citric acid.  **WARNING: FOR IN-VITRO DIAGNOSTIC USE. DO NOT INGEST – IRRITANT.   
Preparation for Use:** Pour 11 L of deionized water into the Destain vat. Add the entire package of Destain. Mix well until completely dissolved.   
**Storage and Stability:** Store the Destain at 15 to 30°C. It is stable until the expiration date on the package.   
**Signs of Deterioration:** Discard if solution becomes cloudy.

**INSTRUMENT**

A SPIFE Touch Analyzer must be used to apply sample, electrophorese, stain, destain and dry the gel. Refer to the appropriate Operator’s Manual for detailed instructions.

**SPECIMEN COLLECTION AND HANDLING**

**Specimen:** The specimen may be serum, cerebrospinal fluid (CSF) or urine. Serum specimens should be free of hemolysis or lipemia. A fibrinogen band, which may obscure the beta-gamma zone, will appear in plasma samples.

**Storage:** Fresh serum is the specimen of choice. If storage is necessary, samples may be stored covered at 2 to 8°C for 48 hours.

**Specimen Preparation:**

**Serum:** Dilute serum samples 1:2 with 0.85% saline solution (1 part serum and 1 part 0.85% saline solution).

**Urine:** Urine samples may be run neat, diluted or concentrated. One application or three applications can be made to obtain desired intensity.

To concentrate urine, shake samples to homogenize. Centrifuge desired volume at 2000 x g for 5 minutes. Remove supernatant and concentrate as follows:

Total Protein (mg/dL) Conc. Factor

< 50 100x

50-100 50x

100-300 25x

300-600 10x

> 600 5x

**CSF:** CSF samples may be used after proper concentration of 10-50x.

**PROCEDURE**

**Materials provided:** The following materials needed for the procedure are contained in the SPIFE SPE Hi Res-20 kit (Cat. No. 3430). Individual items are not available.

SPIFE SPE Hi Res-20 Gels (10)

Acid Violet Stain (1 vial)

REP Blotter C (10)

Blade Applicator Kit (10)

Citric Acid Destain (1 pkg)

**Materials provided by Helena Laboratories but not contained in the kit:**

**Item Cat. No.**

SPIFE Touch Analyzer 1068

Hi Res Protein Marker 5141

Gel Block Remover 1115

REP Prep 3100

Applicator Blade Weights 3387

Disposable Sample Cups 3369

SPIFE Dispo Cup Tray 3370

**Materials needed but not provided:**

10% Glacial Acetic Acid

0.85% Saline Solution

**STEP-BY-STEP METHOD**

**I. Sample Preparation**

**No. of Serum Urine CSF Hi Res**

**Applications Marker**

1 1:2 with saline neat, diluted –––––– neat

or concentrated

3 –––––––––––– neat, diluted 10-50x 1:3 with

or concentrated saline

**1. Serum**   
Dilute each serum sample 1:2 with 0.85% saline solution (1 part serum and 1 part 0.85% saline solution). The Hi Res Marker should be run neat. Only one application is used.

**2. Urine**   
Urine samples may be run neat, diluted or concentrated as described in Specimen Preparation. One application of urine can be run on the same gel with serum samples. If one application of urine is used, the marker should be run neat.   
However, if three applications of urine are used, the marker should be diluted 1:3 with saline. Three applications of urine cannot be run with the serum specimens.

**3. CSF**   
CSF samples should be concentrated 10-50x. The marker should be diluted 1:3 with saline. Three applications of CSF are needed and cannot be run with serum specimens.

**II. Instrument Setup**

1. Remove one Disposable Applicator Blade from the packaging.

2. Place the Applicator Blade into the vertical slot numbered 8 in the Applicator Assembly.  **Note: The Applicator Blade will only fit into the slots in the Applicator Assembly one way; do not try to force the Applicator Blade into the slots.**

3. Place an Applicator Blade Weight on top of the Applicator Blade. When placing the weight on the blade, position the weight with the thick side to the right.

4. Slide the Disposable Sample Cups into the middle row of the Cup Tray numbered 21 to 40.

5. Pipette 20 mL of the appropriate sample into the cups. Cover the tray until ready for use.

**III. Gel Preparation**

1. Remove the gel from the protective packaging and discard overlay.

2. Dispense approximately 2 mL of REP Prep onto the left side of the electrophoresis chamber.

3. Place the left edge of the gel over the REP Prep aligning the round hole on the left pin of the chamber. Gently lay the gel down on the REP Prep, starting from the left side and ending on the right, fitting the obround hole over the right pin. Use lint-free tissue to wipe around the edges of the plastic gel backing, especially next to electrode posts, to remove excess REP Prep. Make sure no bubbles remain under the gel.

4. Place a REP Blotter C on the gel with the longer edge parallel with the gel blocks. Gently blot the entire gel using slight fingertip pressure on the blotter and remove the blotter.

5. Clean the electrodes with deionized water before and after each use. Wipe with a lint free tissue.

6. Place a carbon electrode on the outside ledge of each gel block outside the magnetic posts. Improper contact between electrode and the gel block may cause skewed patterns. Close the chamber lid.

7. Use the arrows under **SEPARATOR UNIT** to select the appropriate test. To check parameters, select test and press **SETUP**.

**IV. Parameters**

**Separator Unit**

**• Serum and/or urine**

**Load Sample** Prompt: None

Time: 0:30

Temperature: 21°C

Speed: 1

**Apply Sample** Prompt: None

Time: 0:30

Temperature: 21°C

Speed: 1

Location: 1

**Electrophoresis** Prompt: None

Time: 18:00

Temperature: 17°C

Voltage: 525 V

mA: 90 mA

**Dry** Prompt: Remove Gel Blocks

Time: 12:00

Temperature: 54°C

**End**

**• Urine and/or CSF**

**Load Sample 1** Prompt: None

Time: 0:30

Temperature: 21°C

Speed: 1

**Apply Sample 1** Prompt: None

Time: 0:30

Temperature: 21°C

Speed: 1

Location: 1

**Load Sample 2** Prompt: None

Time: 0:30

Temperature: 21°C

Speed: 1

**Apply Sample 2** Prompt: None

Time: 0:30

Temperature: 21°C

Speed: 1

Location: 1

**Load Sample 3** Prompt: None

Time: 0:30

Temperature: 21°C

Speed: 1

**Apply Sample 3** Prompt: None

Time: 1:00

Temperature: 21°C

Speed: 1

Location: 1

**Absorb** Prompt: None

Time: 1:00

Temperature: 21°C

**Electrophoresis** Prompt: None

Time: 18:00

Temperature: 17°C

Voltage: 525 V

mA: 90 mA

**Dry** Prompt: Remove Gel Blocks

Time: 12:00

Temperature: 54°C

**End**

**Stainer Unit**

**• Serum, CSF or urine**

**Stain** Prompt: None

Time: 4:00

Recirculation: Off

Valve: 5

Fill, Drain

**Destain 1** Prompt: None

Time: 3:00

Recirculation: On

Valve: 2

Fill, Drain

**Destain 2** Prompt: None

Time: 2:00

Recirculation: On

Valve: 2

Fill, Drain

**Destain 3**  Prompt: None

Time: 1:00

Recirculation: On

Valve: 2

Fill, Drain

**Dry 1** Prompt: None

Time: 12:00

Temperature: 63°C

**End**

**V. Electrophoresis**

1. Open the chamber lid and place the Cup Tray with samples on the SPIFE Touch. Align the holes in the tray with the pins on the instrument. Close the chamber lid.

2. Use the arrows under **SEPARATOR UNIT** to select the appropriate test. Press **START** and choose an operation to proceed. The SPIFE Touch will apply the samples, electrophorese and beep when completed.

3. After electrophoresis is complete, open the chamber lid and use the Gel Block Remover to remove the gel blocks. Dispose of blades and cups as biohazardous waste. Place one electrode across each end of the gel to prevent curling during drying.

4. Close the chamber lid and press the **CONTINUE** button to dry the gel.

**VI. Visualization**

1. After the gel has been dried, open the chamber lid and carefully remove the gel from the electrophoresis chamber.

2. Remove the Gel Holder from the stainer unit. Attach the gel to the holder by placing the round hole in the gel backing over the left pin on the holder and the obround hole over the right pin on the holder.

3. Place the Gel Holder with the attached gel facing backwards into the stainer unit.

4. Use the arrows under **STAINER UNIT** to select the appropriate test. Press **START** and choose an operation to proceed. The instrument will stain, destain and dry the gel.

5. When the gel has completed the process, the instrument will beep. Remove the Gel Holder from the stainer.

**Stability of End Product:**

The completed dried SPIFE SPE Hi Res-20 Gel is stable for an indefinite period of time.

**Quality Control:**

The Hi Res Protein Marker (Cat. No. 5141) may be used to verify appropriate protein band separation and stain sensitivity. Refer to the package insert for more information.

**RESULTS**

**Plasma Proteins**

Figure 1 shows the relative position of most of the plasma proteins.



**Figure 1:** Illustration of relative band positions

**Urine Proteins**

An electrophoretic pattern of normal urine will show a trace of albumin and sometimes a faint transferrin band.

The urine pattern in glomerular proteinuria usually consists of strong bands of albumin, both a1 acid glycoprotein and a1-antitrypsin in a broad a1 zone and transferrin b1 region. The serum pattern shows marked decreases in these proteins with increases in the large proteins which are retained by the glomerulus.

The urine pattern in tubular proteinuria usually consists of a faint albumin band, a double band in the a2 region due to a2-microglobulin, a strong band in the mid-beta region due to b2-microglobulin and, sometimes, diffuse background staining in the gamma region due to free light chains. Chronic renal disease or renal failure can lead to damage of both glomerulus and tubules. This results in a combined pattern with both “glomerular types” and “tubular type” proteins appearing in the urine.

**Cerebrospinal Fluid Proteins**

When CSF is concentrated, the pattern from a normal adult shows a prominent pre-albumin fraction that migrates slightly faster than plasma prealbumin. Albumin is the major band on electrophoresis, comprising from 55 to 75% of the normal CSF protein. The a1 band consists primarily of a1-antitrypsin, the a-lipoprotein fraction being greatly decreased. The a2 region is not a dominant fraction, as with plasma, owing to relative decreases in large proteins such as a2-macroglobulin and the polymeric haptoglobin phenotypes. Transferrin is detected in the b1 region and the major b2 protein is a carbohydrate-deficient "CSF-specific" transferrin. The gamma region, consisting almost exclusively of immunoglobulin G, can show some very faint banding in normal samples. The cathodal end of this zone often contains a low-Mr non-immunoglobulin protein, referred to as gamma trace, which is perhaps synthesized within the central nervous system, but has undetermined clinical significance.

**LIMITATIONS**

**High resolution protein electrophoresis is less sensitive than isoelectric electric focusing with IgG immunoblotting for detection of oligoclonal bands.**9,10,11,12 Helena Laboratories SPIFE IgG Isoelectric Focusing (Cat. No. 3385 or 3389) is recommended for screening and diagnosis of multiple sclerosis. Aging of serum samples will cause the C3 band to migrate in the transferrin region. Fresh specimens only should be tested, and they should not be hemolyzed or lipemic. Samples should be at room temperature before use to prevent cryoprecipitation at the application point. Gels which do not lay flat in the chamber, or those with surface artifacts, should not be used.

**INTERPRETATION OF RESULTS**

**Serum**

High resolution protein electrophoresis patterns are primarily interpreted by comparing the relative intensities of the bands obtained on unknown specimens with those obtained on known normal individuals. One of the most common abnormal serum protein patterns is that observed in the non-specific inflammatory response which is characterized by an increase in a1-antitrypsin and haptoglobin with decreased prealbumin, albumin and transferrin. While it is not useful in establishing a general diagnosis, it is useful in monitoring a patient’s response to therapy. Other examples of clinically important variations are:

- elevation of the transferrin band, suggesting a low level of iron

- presence of monoclonal proteins, suggesting abnormalities of the immune system

- low haptoglobin, suggesting elevated RBC turnover or in-vitro hemolysis

- CRP presence, indicating an acute inflammatory response

- low prealbumin, albumin and transferrin with diffuse hypergammaglobulinemia, suggesting chronic inflammation, infection or antigenic stimulation

- low C3 on fresh samples, suggesting complement consumption.

**Urine**

High resolution protein electrophoresis is an excellent analytical technique to gain a broad overview of urine proteins.3,8 Glomerular-typed proteinuria, tubular-type proteinuria as well as mixed glomerular-tubular patterns and the various overflow states can be easily distinguished and characterized, thus providing useful information on specific functions within the nephron.

**CSF**

Oligoclonal immunoglobulin patterns can be seen in both serum and cerebrospinal fluid as faint bands in the gamma zone. They are usually multiple homogeneous, narrow and discrete in appearance. When seen in serum, the bands indicate the presence of immune complexes which are associated with Hodgkins disease or a non-specific early immune response to various disease states. In the cerebrospinal fluid their presence is supportive evidence for the diagnosis of multiple sclerosis (MS) in the proper clinical setting. Oligoclonal bands in serum are not indicative of MS. An oligoclonal pattern in the CSF is present in more than 90% of MS patients at some time during the course of the disease. It may be less sensitive during an initial attack and is not completely specific for MS. **High resolution protein electrophoresis is less sensitive than isoelectric focusing with IgG immunoblotting for detection of oligoclonal bands.** Other diseases associated with an oligoclonal pattern include subacute sclerosing panencephalitis and some infections of the central nervous system.13,14

**BIBLIOGRAPHY**

1. Laurell CB. 1972. Composition and Variation of the Gel Electrophoretic Fractions of Plasma, Cerebrospinal Fluid and Urine. Scand J Clin Lab Invest. 29 (24 Suppl):71-82.

2. Killingsworth LM, Cooney SK, Tyllia MM, Killingsworth CE. 1980. Protein Analysis, Deciphering Cerebrospinal Fluid Patterns, Diag Med. March/April:1-7.

3. Killingsworth LM, Cooney SK, Tyllia MM. 1980. Protein Analysis, Finding Clues to Disease in Urine. Diag Med. May/June:69-75.

4. Killingsworth LM. 1982. Clinical Applications of Protein Determinations in Biological Fluids Other Than Blood. Clin Chem. 28(5):1093-1102.

5. Ritzmann SE, Daniels JC. 1979. Diagnostic Proteinology: Separation and Characterization of Proteins, Qualitative and Quantitative Assays, in Laboratory Medicine. Hagerstown (MD): Harper and Row, Inc.

6. Killingsworth LM, Cooney SK, Tyllia MM. 1980. Protein Analysis. Diag Med. Jan/Feb: 3-15.

7. Killingsworth LM. 1979. Plasma Protein Patterns in Health and Disease. CRC Critical Reviews in Clinical Laboratory Sciences. August:1-30.

8. Peterson PA, Ervin PE, Beggard I. 1969. Differentiation of Glomerular, Tubular and Normal Proteinuria: Determinations of Urinary Excretion of β2-microglobulin, Albumin and Total Protein. J Clin Invest. 48:1189- 1198.

9. Fortini AS, Sanders EL, Weinshenker BG, Katzmann JA. 2003. Cerebrospinal Fluid Oligoclonal Bands in the Diagnosis of Multiple Sclerosis. Am J Clin Pathol. 120(5): 672-5.

10. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Ohman S, Racke MK, Sharief M, Sindic CJ, et al. 2005. Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis. Archives of Neurology. 62:865-70.

11. Andersson M, Alvarez-Cermeño J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Grønning M. 1994. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 57(8):897-902.

12. Trbojevic-Cepe M. 2004. Detection of oligoclonal Ig Bands: Clinical Significance and trends in methodological Improvement. EJIFCC. [published 2004 Aug 31]; 15(3):86-94. (https://www.ifcc.org/media/476991/ejifcc2004vol15no3pp086-094.pdf)

13. Miller JR, Burke AM, Bever CT. 1983. Occurrence of oligoclonal bands in multiple sclerosis and other CNS diseases. Ann Neurol. 13(1): 53-8.

14. Chu AB, Sever JL, Madden DL, Iivanainen M, Leon M, Wallen W, Brooks BR, Lee YJ, Houff S. 1983. Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases. Ann Neurol. 13(4):434-9.

For Sales, Technical and Order Information, and Service Assistance, call 800-231-5663 toll free.

Helena Laboratories warrants its products to meet our published specifications and to be free from defects in materials and workmanship. Helena’s liability under this contract or otherwise shall be limited to replacement or refund of any amount not to exceed the purchase price attributable to the goods as to which such claim is made. These alternatives shall be buyer’s exclusive remedies.

In no case will Helena Laboratories be liable for consequential damages even if Helena has been advised as to the possibility of such damages.

The foregoing warranties are in lieu of all warranties expressed or implied including, but not limited to the implied warranties of merchantability and fitness for a particular purpose.





Pro 228

8/19(2)